Category WELLNESS

PIER MARIA FORNASARI
2026-07-29

In calcium-replete older women, calcium supplements had little effect on the response to antiresorptives, whereas low protein intake blunted their benefits. 

In older women with adequate calcium intake receiving osteoporosis medications, calcium supplements did not provide additional improvements in hip bone mineral density (BMD) or bone strength. However, a low dietary protein intake was associated with reduced skeletal benefits of antiresorptive therapy. METHODOLOGY TAKEAWAY IN PRACTICE “[The study] findings do not support the routine use of CaS [calcium

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-22

Prevention of heart failure: A scientific statement of the Heart Failure Association, the European Association of Preventive Cardiology, and the Association of Cardiovascular Nursing & Allied Professions of the ESC, and the ESC Council on Hypertension

Heart failure already affects more than 60 million people worldwide and is one of the leading causes of hospitalization among people over the age of 65. Although it is commonly associated with advanced cardiovascular disease, it actually develops over many years, often without symptoms. Authors of a new expert statement published in the European Heart

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-22

Caffeine and cardiovascular health: a new American Heart Association review

Although the relationship between caffeine and cardiovascular health is complex, the latest research indicates consuming up to 5 cups of caffeinated coffee per day (up to 400 mg of caffeine/day) is safe for most adults and may be linked to cardiovascular health benefits in some individuals, according to a new American Heart Association scientific statement.

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-21

New position statement calls for systematic bone health optimization before joint replacement and spinal fusion surgery

International expert group reframes arthroplasty and spinal fusion complications as a shared problem of implant fixation failure, and issues clinical recommendations for peri-operative bone health care. A new position statement from the International Osteoporosis Foundation’s (IOF) Committee of Scientific Advisors Fracture Working Group urges orthopaedic surgeons and bone health specialists to work together to assess and treat

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-21

New 2026 Dyslipidemia Guidelines Will Shift Statins to Younger and Lower-Risk U.S. Adults

Studies assess population health impacts of the guideline on dyslipidemia Key Takeaways The new American cholesterol guideline would not make more Americans statin users per se, but instead shift the profile of people who should initiate lipid-lowering therapy to those younger and lower risk, research indicated. Based on National Health and Nutrition Examination Survey (NHANES)

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-19

FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

First oral PCSK9 inhibitor provides an additional treatment option for adults with hypercholesterolemia The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-15

Blood-Based Test Can Predict Risk of Developing Symptoms of Alzheimer’s Up to a Decade Early

Key Takeaways A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged around the extent to which such tests can accurately predict whether a cognitively healthy individual will go on to develop cognitive impairment—a key symptom of Alzheimer’s disease. A new, international study involving researchers across three

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2026-07-10

Did you know that most obesity drugs do not significantly improve quality of life or reduce cardiovascular risk?

A study published in The BMJ reveals that most obesity medications do not significantly improve quality of life and few show cardiovascular benefits. In an article by Ingrid Torjesen, a journalist at the British Medical Journal, published on The BMJ website, she explains that drugs used to treat obesity , such as semaglutide (Wegovy) and tirzepatide (Mounjaro),

Read More

No Comments InWELLNESS